Saturday 17 October 2026
Export ADVB’s income statement to Excel — free account
Advanced Biomed Inc.
ADVB Healthcare Diagnostics & Research
Advanced Biomed Inc.’s revenue for fiscal 2026 (year ended June 2026) was $127,600.00. In the quarter to June 2026, EPS grew 54.8% and free cash flow fell 101.3%, each against the same quarter a year earlier.
3.98
0.90
−18.44%
Follow ADVB
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 84.77% | 79.17% | 86.84% | (144.85%) |
+7 more TTM periods Free account |
|
| 36.47% | 55.78% | 57.12% | (108.29%) | ||
ROIC |
(33.43%) | (10.97%) | (10.97%) | (196.06%) | |
Return on Tangible Assets |
54.39% | 57.47% | 45.80% | (109.74%) | |
Free Cash Flow per Share |
(3.61) | (2.29) | (5.65) | (5.93) | |
Free Cash Flow |
(4.53) | (2.94) | (6.11) | (6.42) | |
Capital Expenditures |
(2.58) | (0.04) | (0.04) | (0.01) | |
| Other line items | |||||
Cash ROIC |
(35.77%) | (24.92%) | (50.59%) | (113.40%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
(0.29) | (0.55) | (1.39) | 1.90 | |
Depreciation/Fixed assets |
— | 3.67 | 3.43 | 1.03 | |
Capex/Depreciation |
0.00 | (0.11) | (0.11) | (0.05) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.55) | (2.26) | (5.62) | (5.92) | |
Capex per Share |
(2.06) | (0.03) | (0.03) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 15 Oct 2026